TY - JOUR
T1 - Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo
AU - Zeissig, Mara N.
AU - Hewett, Duncan R.
AU - Panagopoulos, Vasilios
AU - Mrozik, Krzysztof M.
AU - To, L. Bik
AU - Croucher, Peter I.
AU - Zannettino, Andrew C.W.
AU - Vandyke, Kate
N1 - Publisher Copyright:
©2021 Ferrata Storti Foundation
PY - 2021/12
Y1 - 2021/12
N2 - Multiple ability (BM), enter of myeloma MM the plasma circulation (MM) cells disease (PC) and progression to disseminate egress from is to dependent the distal bone BM marrow on sites. the Expression of the chemokine CXCL12 by BM stromal cells is crucial for MM PC retention within the BM. However, the mechanisms which overcome CXCL12-mediated retention to enable dissemination are poorly understood. We have previously identified that treatment with the CCR1 ligand CCL3 inhibits the response to CXCL12 in MM cell lines, suggesting that CCL3/CCR1 signaling may enable egress of MM PC from the BM. Here, we demonstrated that CCR1 expression was an independent prognostic indicator in newly diagnosed MM patients. Furthermore, we showed that CCR1 is a crucial driver of dissemination in vivo, with CCR1 expression in the murine MM cell line 5TGM1 being associated with an increased incidence of bone and splenic disseminated tumors in C57BL/KaLwRij mice. Furthermore, we demonstrated that CCR1 knockout in the human myeloma cell line OPM2 resulted in a >95% reduction in circulating MM PC numbers and BM and splenic tumor dissemination following intratibial injection in NSG mice. Therapeutic targeting of CCR1 with the inhibitor CCX9588 significantly reduced OPM2 or RPMI-8226 dissemination in intratibial xenograft models. Collectively, our findings suggest a novel role for CCR1 as a critical driver of BM egress of MM PC during tumor dissemination. Furthermore, these data suggest that CCR1 may represent a potential therapeutic target for the prevention of MM tumor dissemination.
AB - Multiple ability (BM), enter of myeloma MM the plasma circulation (MM) cells disease (PC) and progression to disseminate egress from is to dependent the distal bone BM marrow on sites. the Expression of the chemokine CXCL12 by BM stromal cells is crucial for MM PC retention within the BM. However, the mechanisms which overcome CXCL12-mediated retention to enable dissemination are poorly understood. We have previously identified that treatment with the CCR1 ligand CCL3 inhibits the response to CXCL12 in MM cell lines, suggesting that CCL3/CCR1 signaling may enable egress of MM PC from the BM. Here, we demonstrated that CCR1 expression was an independent prognostic indicator in newly diagnosed MM patients. Furthermore, we showed that CCR1 is a crucial driver of dissemination in vivo, with CCR1 expression in the murine MM cell line 5TGM1 being associated with an increased incidence of bone and splenic disseminated tumors in C57BL/KaLwRij mice. Furthermore, we demonstrated that CCR1 knockout in the human myeloma cell line OPM2 resulted in a >95% reduction in circulating MM PC numbers and BM and splenic tumor dissemination following intratibial injection in NSG mice. Therapeutic targeting of CCR1 with the inhibitor CCX9588 significantly reduced OPM2 or RPMI-8226 dissemination in intratibial xenograft models. Collectively, our findings suggest a novel role for CCR1 as a critical driver of BM egress of MM PC during tumor dissemination. Furthermore, these data suggest that CCR1 may represent a potential therapeutic target for the prevention of MM tumor dissemination.
UR - http://www.scopus.com/inward/record.url?scp=85095675899&partnerID=8YFLogxK
U2 - 10.3324/haematol.2020.253526
DO - 10.3324/haematol.2020.253526
M3 - Article
C2 - 33147936
AN - SCOPUS:85095675899
SN - 0390-6078
VL - 106
SP - 316
EP - 3187
JO - Haematologica
JF - Haematologica
IS - 12
ER -